A food supplement Lekolid, providing clinically proven benefits for women suffering from endometriosis, has been launched in the Bosnian market in partnership with Rhei Life and Oktal Pharma. Lekolid uses a unique triple mechanism of action – anti-inflammatory, anti-oxidative and anti-proliferative for the complete control of the symptoms of endometriosis. The patented ENDOBASP technology provides better absorption and an increased effectiveness. Endometriosis affects roughly 10% or 190 million of reproductive age women and girls globally.
Endometriosis is a disease where tissue similar to the lining of the uterus grows outside the uterus, causing pain and/or infertility. It is a chronic disease associated with severe, life-impacting pain during periods, sexual intercourse, bowel movements and/or urination, chronic pelvic pain, abdominal bloating, nausea, fatigue, and sometimes depression, anxiety, and sterility. Various and broad symptoms of endometriosis mean that healthcare workers are not able to diagnose it easily, resulting in many individuals suffering from it and not being aware of the condition. This can cause a lengthy delay between the onset of the symptoms and diagnosis. At present, there is no known cure for endometriosis and the treatment is usually aimed at symptom control.
“We are proud that our product Lekolid, a highly efficient treatment for women suffering of endometriosis, after having been launched in Serbia, Croatia, Montenegro and North Macedonia, is now available on the Bosnian market as well. The access to early diagnosis and effective treatment of endometriosis is important and we shall continue with awareness raising in order to ensure effective prevention, early diagnosis, and improved management of the disease”, said Katarina Đorđević, Head of Marketing and Product Management Team in Rhei Life.